Integrin αvβ3 a potential prognostic biomarker of chemotherapy response in breast cancer. 

DIAZ ALBUJA JA; STERLE, HELENA; CAYROL, FLORENCIA; PAULAZO, MARÍA ALEJANDRA; CAMPOS HAEDO, MATEO; DEBERNARDI, MERCEDES; ROSEMBLIT, CINTHIA; CREMASCHI, GRACIELA ALICIA; DIAZ FLAQUÉ C.

Congreso; SAFIS + ALACF 2021 Joint meeting. 20-22 October 2021,; 2021

Sociedad Argentina de Fisiologia

Despite the development of novel therapies, breast cancer (BC) tumors are treated withconventional therapy sooner or later. Due to tumor heterogeneity, it is necessary to definenew biomarkers to identify groups with different molecular signature to improve the correcttreatment decision. The impact of thyroid status in BC growth has previously been studied.It has been found alterations of thyroid function during chemotherapy BC treatment anddemonstrated that T3 induces chemosensitization of BC cells. However, the relationshipbetween thyroid hormones (THs) membrane receptor, integrin αvβ3 and BC response tochemotherapy remains unclear. The aim of this study is to evaluate the relationshipbetween THs and integrin αvβ3 expression as prognostic value in BC patients.The mRNA expression of integrin β3 (ITGB3) in TCGA-PanCancer Atlas, BC dataset(1084 patients) were correlated with ABCB1(MDR1) and ABCG2(BCRP), (Pearson, Rscore >0.3 and p